Non-executive director Guo Huaqing increased his holdings of SciClone Pharmaceuticals (02171) by 30,000 shares at a price of HK$14.98 per share.
On December 15th, non-executive director Guo Huaqing increased his holdings in Keji Pharmaceutical (02171) by 30,000 shares, at a price of HK$14.98 per share, with a total amount of HK$449,400.
The latest data from the Hong Kong Stock Exchange shows that on December 15th, non-executive director Guo Huaqing increased his holdings of Keji Medicine (02171) by 30,000 shares, with a price of 14.98 Hong Kong dollars per share, for a total amount of 449,400 Hong Kong dollars. After the increase, the latest number of shares held is approximately 224 million, with a shareholding ratio of 38.75%.
Related Articles
US Stock Market Move | AI application software stocks rise, Applovin (APP.US) up more than 6%
US Stock Market Move | Orforglipron's oral weight-loss drug program achieves success in Phase III trial, causing Eli Lilly (LLY.US) stock to rise more than 3%.
US Stock Market Move | Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) rose more than 3%. Morgan Stanley predicts that the company's gross profit margin will surpass 60% in the fourth quarter.
US Stock Market Move | AI application software stocks rise, Applovin (APP.US) up more than 6%
US Stock Market Move | Orforglipron's oral weight-loss drug program achieves success in Phase III trial, causing Eli Lilly (LLY.US) stock to rise more than 3%.
US Stock Market Move | Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR (TSM.US) rose more than 3%. Morgan Stanley predicts that the company's gross profit margin will surpass 60% in the fourth quarter.
